Radioimmunotherapy of brain tumor

Giovanni Paganelli, Mirco Bartolomei, Chiara Grana, Mahila Ferrari, Paola Rocca, Marco Chinol

Research output: Contribution to journalArticlepeer-review


Despite years of intensive research, the prognosis of high-grade gliomas (HGG) remains poor, as these tumors are highly resistant to currently available therapies. Therefore, there is a need for the development of new therapeutic strategies, such as the use of monoclonal antibodies (MoAbs) in association with radioisotopes, in order to achieve better responses and prognosis. This article describes our experience in radioimmunotherapy (RIT) with MoAbs and tumor pretargeting with the avidin-biotin system, either in systemic or locoregional administrations. This therapy offers the exciting prospect of increasing the specificity of tumor cell irradiation with radioisotopes. We suggest that RIT, both systemic and locoregional, should be used as part of a combined modality approach: in combination with surgery, radiotherapy and chemotherapy.

Original languageEnglish
Pages (from-to)518-522
Number of pages5
JournalNeurological Research
Issue number5
Publication statusPublished - Jul 2006


  • Antibodies
  • Glioblastoma
  • Radioimmunotherapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)


Dive into the research topics of 'Radioimmunotherapy of brain tumor'. Together they form a unique fingerprint.

Cite this